Skip to main content
UniHealth

Doctor search

Seema Nagpal, MD

Neurology · Stanford

NPI 1356541759

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nagpal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A96310 · Current

Licensed to practise in California · since 2006 · expires 2027-11-30 · University of Pennsylvania School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$32,812

Medicare paid this office $32,812 for 121 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)43$11,378$158
Long return visit (40+ min)39$8,174$126
New patient visit (60+ min)32$4,811$150
Return visit (30+ min)17$2,847$119
Return visit (30+ min)16$1,934$84

Who their Medicare patients are

121 Original Medicare patients in 2024. Average age 70 · Women 60% · Also on Medicaid 22% · Health risk score 2.46. Sicker patients than 9 in 10 peers; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 60% · Cancer 51% · Stroke 29% · Diabetes 27% · Depression 23% · Coronary heart disease 22% · Chronic kidney disease 21% · COPD 15% · Heart failure 12% · Atrial fibrillation 12% · Dementia 9%.

The office billed $130,497, Medicare allowed $43,111 and paid $32,812; for 255 services of 15 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024121255702.46$130,497$32,812
2023118248692.47$128,034$29,988
2022146290692.45$160,349$35,586
202196219692.07$121,253$26,264
202081179682.21$80,494$17,172
201985171672.04$24,377$15,557
201886178692.09$26,638$16,919
201764116682.11$30,093$11,719
2016117190682.40$57,674$17,341
2015138317681.99$102,169$29,809
2014106201681.90$57,983$18,701
2013116279691.91$86,602$24,521

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)93$21,531$124
New patient visit (60+ min)36$5,845$162
Return visit (30+ min)12$1,059$88

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)95$24,684$129
New patient visit (60+ min)33$5,435$165
Return visit (30+ min)19$1,664$83

2021: 4 services

Original Medicare services billed in 2021
Long return visit (40+ min)66$17,335$130
New patient visit (60+ min)36$6,318$175
Return visit (30+ min)15$1,537$81
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or12$869$30

2020: 3 services

Original Medicare services billed in 2020
Long return visit (40+ min)45$7,834$103
New patient visit (60+ min)23$3,536$154
Return visit (30+ min)38$3,469$64

2019: 3 services

Original Medicare services billed in 2019
Long return visit (40+ min)50$8,669$94
New patient visit (60+ min)26$3,586$138
Return visit (30+ min)35$2,983$61

2018: 3 services

Original Medicare services billed in 2018
Long return visit (40+ min)46$7,940$97
New patient visit (60+ min)29$4,207$145
Return visit (30+ min)36$3,586$64

2017: 3 services

Original Medicare services billed in 2017
Long return visit (40+ min)27$3,686$97
New patient visit (60+ min)24$3,608$150
Return visit (30+ min)25$2,761$67

2016: 3 services

Original Medicare services billed in 2016
New patient visit (60+ min)41$6,057$148
Long return visit (40+ min)49$6,039$84
Return visit (30+ min)39$3,243$58

2015: 6 services

Original Medicare services billed in 2015
Long return visit (40+ min)55$7,575$96
New patient visit (60+ min)35$5,081$145
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$4,183$93
Return visit (30+ min)39$3,464$64
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,256$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$2,591$65

2014: 3 services

Original Medicare services billed in 2014
Long return visit (40+ min)49$6,303$97
Return visit (30+ min)47$4,629$69
New patient visit (60+ min)27$4,038$150

2013: 5 services

Original Medicare services billed in 2013
Long return visit (40+ min)33$6,505$92
Return visit (30+ min)49$6,365$64
New patient visit (60+ min)32$4,543$142
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,805$175
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,368$62

Medicaid work

$4,261 in 2023

Medicaid paid $4,261 for 87 billed services this clinician did in 2023, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Long return visit (40+ min)87$4,261
Medicaid work by year
202387116$4,261

Money from drug and device companies

$47,782 in 2025

Industry payments by year
2025830$25,716$47,782
202448$11,413$11,743
202346$2,940$3,437
202246$1,670$1,898
202139$2,000$3,256
202044$2,666$2,709
201938$1,100$2,173

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Daiichi SankyoDatroway$38,312
20 payments
  • Travel for Datroway · 2025-11-05 · $622
  • Travel for Datroway · 2025-11-05 · $40
  • Travel for Datroway · 2025-11-05 · $58
  • Travel for Datroway · 2025-11-05 · $39
  • Meals for Datroway · 2025-11-05 · $29
  • Meals for Datroway · 2025-11-05 · $36
  • Meals for Datroway · 2025-11-05 · $26
  • Consulting for Datroway · 2025-10-15 · $9,113
  • Travel for Datroway · 2025-09-08 · $8,815
  • Consulting for Datroway · 2025-06-18 · $5,400
  • Meals for Datroway · 2025-06-04 · $21
  • Meals for Datroway · 2025-06-04 · $25
  • Travel for Datroway · 2025-06-04 · $41
  • Travel for Datroway · 2025-06-04 · $40
  • Travel for Datroway · 2025-06-04 · $18
  • Travel for Datroway · 2025-06-04 · $16
  • Consulting for Datroway · 2025-05-28 · $1,013
  • Travel for Enhertu · 2025-05-16 · $11,615
  • Travel for Enhertu · 2025-05-16 · $334
  • Consulting for Datroway · 2025-04-02 · $1,013
SpringWorks TherapeuticsGomekli$3,713
1 payment
  • Consulting for Gomekli · 2025-11-22 · $3,713
Catalyst PharmaceuticalsFirdapse$2,367
2 payments
  • Honoraria for Firdapse · 2025-11-20 · $2,250
  • Meals for Firdapse · 2025-11-20 · $117
Menarini Silicon BiosystemsCellsearch$1,846
2 payments
  • Consulting for Cellsearch · 2025-11-30 · $615
  • Consulting for Cellsearch · 2025-10-31 · $1,230
NovocureNone$750
1 payment
  • Honoraria · 2025-05-08 · $750
Deciphera PharmaceuticalsNone$620
1 payment
  • Paid to speak or teach · 2025-12-02 · $620
See all 29 published payments
Every published payment
Deciphera PharmaceuticalsPaid to speak or teach · 2025-12-02None$620
Menarini Silicon BiosystemsConsulting · 2025-11-30Cellsearch$615
SpringWorks TherapeuticsConsulting · 2025-11-22Gomekli$3,713
Catalyst PharmaceuticalsHonoraria · 2025-11-20Firdapse$2,250
Catalyst PharmaceuticalsMeals · 2025-11-20Firdapse$117
Jazz PharmaceuticalsMeals · 2025-11-18Modeyso$101
Daiichi SankyoTravel · 2025-11-05Datroway$622
Daiichi SankyoTravel · 2025-11-05Datroway$40
Daiichi SankyoTravel · 2025-11-05Datroway$58
Daiichi SankyoTravel · 2025-11-05Datroway$39
Daiichi SankyoMeals · 2025-11-05Datroway$29
Daiichi SankyoMeals · 2025-11-05Datroway$36
Daiichi SankyoMeals · 2025-11-05Datroway$26
Menarini Silicon BiosystemsConsulting · 2025-10-31Cellsearch$1,230
Servier PharmaceuticalsMeals · 2025-10-17Voranigo$72
Daiichi SankyoConsulting · 2025-10-15Datroway$9,113
Daiichi SankyoTravel · 2025-09-08Datroway$8,815
Daiichi SankyoConsulting · 2025-06-18Datroway$5,400
Daiichi SankyoMeals · 2025-06-04Datroway$21
Daiichi SankyoMeals · 2025-06-04Datroway$25
Daiichi SankyoTravel · 2025-06-04Datroway$41
Daiichi SankyoTravel · 2025-06-04Datroway$40
Daiichi SankyoTravel · 2025-06-04Datroway$18
Daiichi SankyoTravel · 2025-06-04Datroway$16
Daiichi SankyoConsulting · 2025-05-28Datroway$1,013
Daiichi SankyoTravel · 2025-05-16Enhertu$11,615
Daiichi SankyoTravel · 2025-05-16Enhertu$334
NovocureHonoraria · 2025-05-08None$750
Daiichi SankyoConsulting · 2025-04-02Datroway$1,013
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $11,743

Payments by company in 2024
SpringWorks TherapeuticsNone$3,908
2 payments
  • Consulting · 2024-06-04 · $3,713
  • Meals · 2024-06-04 · $195
Servier PharmaceuticalsNone$3,455
3 payments
  • Consulting · 2024-12-16 · $3,320
  • Meals · 2024-11-22 · $125
  • Meals · 2024-11-22 · $10
Daiichi SankyoNone$2,685
2 payments
  • Consulting · 2024-11-28 · $1,880
  • Consulting · 2024-11-28 · $806
Novartis PharmaceuticalsMekinist$1,695
1 payment
  • Consulting for Mekinist · 2024-03-27 · $1,695

2023: $3,437

Payments by company in 2023
Telix PharmaceuticalsIlluccix$2,276
2 payments
  • Honoraria for Illuccix · 2023-10-10 · $2,000
  • Meals for Illuccix · 2023-08-23 · $276
Bayer Healthcare PharmaceuticalsVitrakvi$940
1 payment
  • Consulting for Vitrakvi · 2023-09-12 · $940
NovocureOptune$162
2 payments
  • Meals for Optune · 2023-12-01 · $82
  • Meals for Optune · 2023-05-26 · $79
Gilead SciencesTrodelvy$59
1 payment
  • Meals for Trodelvy · 2023-09-10 · $59

2022: $1,898

Payments by company in 2022
Novocure GmbHOptune$1,250
2 payments
  • Consulting for Optune · 2022-12-21 · $750
  • Consulting for Optune · 2022-01-10 · $500
MedtronicNone$420
1 payment
  • Consulting · 2022-03-07 · $420
Regeneron Healthcare SolutionsLibtayo$152
1 payment
  • Meals for Libtayo · 2022-06-02 · $152
NovocureOptune$77
2 payments
  • Meals · 2022-11-18 · $49
  • Meals for Optune · 2022-03-03 · $27

2021: $3,256

Payments by company in 2021
Novocure GmbHOptune$2,000
2 payments
  • Consulting · 2021-08-11 · $1,000
  • Consulting for Optune · 2021-01-07 · $1,000
Servier PharmaceuticalsNone$1,008
5 payments
  • Travel · 2021-11-17 · $267
  • Meals · 2021-11-17 · $5
  • Travel · 2021-11-17 · $227
  • Travel · 2021-11-17 · $451
  • Travel · 2021-11-17 · $59
NovocureOptune$249
2 payments
  • Meals for Optune · 2021-09-15 · $116
  • Meals for Optune · 2021-05-14 · $132

2020: $2,709

Payments by company in 2020
SeagenTukysa$1,513
1 payment
  • Consulting for Tukysa · 2020-12-01 · $1,513
BiogenNone$800
1 payment
  • Consulting · 2020-12-30 · $800
CepheidGenexpert$353
1 payment
  • Consulting for Genexpert · 2020-11-10 · $353
NovocureOncology$44
1 payment
  • Meals for Oncology · 2020-01-30 · $44

2019: $2,173

Payments by company in 2019
BiogenNone$1,100
1 payment
  • Consulting · 2019-09-12 · $1,100
NovocureOncology$888
6 payments
  • Meals for Oncology · 2019-11-23 · $34
  • Meals for Oncology · 2019-11-21 · $145
  • Meals for Oncology · 2019-10-08 · $33
  • Meals for Oncology · 2019-09-26 · $60
  • Travel for Oncology · 2019-09-03 · $5
  • Travel for Oncology · 2019-09-03 · $612
Agios PharmaceuticalsNone$185
1 payment
  • Meals · 2019-11-22 · $185

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2024Their institution$365,568
Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2023Their institution$116,782
Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2025Their institution$110,929
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023Their institution$81,748
Regeneron Pharmaceuticals, Inc. · A First-in-Human Study of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody To Programmed Death - 1 Pd 1, As Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies · 2019Their institution$78,814
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2025Their institution$66,395
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2024Their institution$59,698
Servier Pharmaceuticals LLC · Study of Vorasidenib (Ag-881) in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation (Indigo) · 2021Their institution$57,666
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2022Their institution$47,412
InSightec,LTD · Exablate · 2021Their institution$42,675
Servier BioInnovation · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Ag-881 in Subjects With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation · 2024Their institution$38,576
Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vorasidenib in Subjects With Recurrent, Non-Enhancing, Low-Grade Glioma With An Idh1 Or Idh2 Mutation · 2020Their institution$22,732
Servier BioInnovation · Calaspargase Pegol in Adults With All · 2024Their institution$22,225
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2021Their institution$21,831
Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vorasidenib in Subjects With Recurrent, Non-Enhancing, Low-Grade Glioma With An Idh1 Or Idh2 Mutation · 2021Their institution$12,917
Regeneron Pharmaceuticals, Inc. · A First-in-Human Study of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody To Programmed Death - 1 Pd 1, As Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies · 2020Their institution$8,834
InSightec,LTD · Bt009-Fees · 2022Their institution$6,982
InSightec,LTD · Bt009-Treatments · 2022Their institution$4,441
InSightec,LTD · Pd006,Uf036, Bt009 · 2023Their institution$3,958
InSightec,LTD · Bt009-Irb · 2023Their institution$3,520
InSightec,LTD · Bt009-Treatments · 2023Their institution$1,633

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1356541759
Licence
CA A96310California A96310: Current · expires 2027-11-30
Trained
Perelman School of Med at the University of Pennsylvania, 2004
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Neurology (2084N0400X)
Mailing address
875 Blake Wilbur Drive, Cc2221, Stanford, CA, 94305
NPI first listed
2007-07-23
NPI last updated
2011-05-23

This is when the NPI record was last certified, not a medical board exam.